ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1323

Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma

Lilian SOLE1, Arthur Beck 1, Thomas Barnetche 2 and Pascale Vergne-Salle 3, 1CHU de Limoges, LIMOGES, France, 2CHU, Toulouse, France, 3CHU limoges, Limoges, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ACS and WOMAC, meta-analysis, Osteoarthritis, PRP

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: While there is growing evidences for the efficacy of platelet-rich plasma (PRP), there is still no standardized composition. There are 3 major types of PRP: Leukocytes Rich (LR), Leukocytes Poor (LP), and Autologous Conditioned Serum (ACS) or Plasma Rich in Growth Factor (PRGF) which are without any cells. Since 2014 no meta-analysis tried to compare separately the different type of PRP. The purpose of this meta-analysis was to compare separately each kind of PRP versus hyaluronic acid (HA) for osteoarthritis (OA) to find if one of them stands out.

Methods: Randomized Controlled Trials (RCTs) at least single blinded, comparing the use of PRP an HA for OA were retrieved from PubMed, Cochrane, Embase until May 2019 and from abstracts of EULAR and ACR congrersses for the last 3 years. We chose the most used follow-up time, which was 6 months. Two readers extracted the Western Ontario and McMaster University Arthritis Index (WOMAC) and any other pain scale, and adverse events. The pooled data where analyzed with Review Manager 5.3.5.

Results: 1139 results were screened, 24 RCTs met the inclusion criteria, and only 16 where enough detailed to be meta-analyzed. The present meta-analysis indicated that only PRGF/ACS and LP PRP reduced significantly the WOMAC score compared with HA. The WOMAC was reduced by 5.24 points with LP-PRP and 11.82 points with ACS/PRGF (Fig.1). Concerning the pain scales only the ACS/PRGF group shown a significant difference versus HA (Fig.2). We found no link between injected platelet quantity and WOMAC index.

Conclusion: ACS/PRGF have stronger evidence of efficacy than LP or LR PRP. These results are consistent with the theorical models explaining the ways of action of PRP. Numbers of authors theorizes that anti-inflammatory cytokines contained in the platelets (like IL-1ra, TGF-β, IL-10) are responsible for the effect of PRP, while leukocyte (containing pro-inflammatory cytokines and metalloproteases) are harmful for the cartilage. The principal limit of this meta-analysis is the heterogenicity of the studies probably due to the absence of standardization of PRP, indeed inside this 3 subgroups, the preparations can still differs by the platelet concentration, the activation of platelet -chemical, physical or unactivated- or the injection scheme . No conclusion can be drawn about the superiority of one kind of PRP since we lack face to face studies.

Figure 1: WOMAC changes at 6 months in different subgroups of PRP versus HA

Figure 2: Standardize mean difference of pain scales at 6 months in different subgroups of PRP versus HA


Disclosure: L. SOLE, None; A. Beck, None; T. Barnetche, None; P. Vergne-Salle, None.

To cite this abstract in AMA style:

SOLE L, Beck A, Barnetche T, Vergne-Salle P. Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/autologous-conditioned-serum-and-plasma-rich-in-growth-factors-show-stronger-evidence-of-efficacy-than-other-kinds-of-platelet-rich-plasma/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autologous-conditioned-serum-and-plasma-rich-in-growth-factors-show-stronger-evidence-of-efficacy-than-other-kinds-of-platelet-rich-plasma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology